Viridian shares REVEAL-1 Phase 3 topline results presentation for elegrobart in TED

Viridian Therapeutics, Inc. +3.65% Pre

Viridian Therapeutics, Inc.

VRDN

14.47

14.47

+3.65%

0.00% Pre
  • Viridian published REVEAL-1 Phase 3 topline results presentation for elegrobart in active thyroid eye disease.
  • Trial met primary endpoint at week 24, with 54% proptosis responder rate in Q4W arm versus 18% for placebo (p < 0.0001).
  • Secondary outcomes included 63% proptosis responder rate in Q8W arm versus 18% for placebo, with 51% complete diplopia resolution in Q4W arm versus 16%.
  • Safety profile through week 24 was described as generally well tolerated, with low rate of hearing impairment adverse events.
  • Viridian outlined next steps for elegrobart, with REVEAL-2 chronic TED topline data expected in Q2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.